Hoth Therapeutics reports ‘encouraging’ results from Phase 2a trial of HT-001

Hoth Therapeutics (HOTH) shared encouraging interim safety and efficacy results from its Phase 2a clinical trial of HT-001, designed to address skin toxicities linked to Epidermal Growth Factor Receptor Inhibitors in cancer patients. Data from the open-label portion of the CLEER-001 trial demonstrated remarkable success: 100% of patients achieved the primary efficacy endpoint of an ARIGA score less than or equal to1, showing significant skin toxicity improvement by the six-week mark. 66% of patients reported reduced pain and itching scores, further enhancing quality of life. Crucially, all patients maintained their full EGFRi dosage, preserving the cancer treatment’s full therapeutic effect-a notable improvement compared to past reports showing widespread dose reductions or treatment halts due to skin-related side effects. No treatment-related adverse effects have been reported, reaffirming HT-001’s excellent tolerability.